与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-000791 Size: 5 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-000792 Size: 5 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-000793 Size: 5 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-22-000389 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 内部交易: 2021-12-17,CHIEF FINANCIAL OFFICER,Kirby John J. ,买入,10000普通股, $0.61
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-21-006155 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001104659-21-149581 Act: 34 Size: 429 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 3.01 and 8.01 Accession Number: 0001104659-21-145450 Act: 34 Size: 204 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-21-135695 Act: 34 Size: 255 KB 网页链接
$井寺制药(IDRA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-21-015025 Act: 34 Size: 7 MB 网页链接